Fate Therapeutics
FATE · NASDAQ
$2.06+$0.20 (+10.75%)TodayMarket closed ·
Prev close $1.86
EPS: actual vs estimate
Beat the estimate in 8 of the last 8 quarters, by 9.1% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.2732 | -$0.25 | +8.5% |
| Q1 FY26 | -$0.2856 | -$0.26 | +9.0% |
| Q4 FY25 | -$0.2751 | -$0.27 | +1.9% |
| Q3 FY25 | -$0.2969 | -$0.27 | +9.1% |
| Q2 FY25 | -$0.3493 | -$0.29 | +17.0% |
| Q1 FY25 | -$0.3907 | -$0.32 | +18.1% |
| Q4 FY24 | -$0.4411 | -$0.44 | +0.2% |
| Q3 FY24 | -$0.4409 | -$0.40 | +9.3% |
Earnings calls
- Barclays 27th Annual Global Healthcare Conference 2025
- Citi's 2024 Global Healthcare Conference
- FATE - Earnings call Q1 2024
- Barclays 26th Annual Global Healthcare Conference 2024
- FATE - Earnings call 4 2023
- FATE - Earnings call 3 2023
- FATE - Earnings call Q2 2023
- Earnings call Q2 2023
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.